Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2010

Open Access 01-12-2010 | Research

Health-related quality of life in patients with severe COPD hospitalized for exacerbations - comparing EQ-5D, SF-12 and SGRQ

Authors: Petra Menn, Norbert Weber, Rolf Holle

Published in: Health and Quality of Life Outcomes | Issue 1/2010

Login to get access

Abstract

Background

The aim of this study was to measure HrQoL during acute exacerbations of COPD using generic and disease-specific instruments, and to assess completeness, proportion with best or worst health state, sensitivity to change and discriminative ability for each instrument.

Methods

EQ-5D, SF-12 and SGRQ were obtained from COPD patients with GOLD stage III and IV hospitalized for an acute exacerbation both at admission and discharge. To assess the instruments' properties, utility values were calculated for EQ-5D and SF-12, and a total score was derived from the SGRQ.

Results

Mean utilities ranged from 0.54 (SF-12, stage IV) to 0.62 (EQ-5D, stage III) at admission, and from 0.58 (SF-12, stage IV) to 0.84 (EQ-5D, stage III) at discharge. Completeness was best for EQ-5D and SGRQ, while no utility value for the SF-12 could be calculated for more than 30%. For SGRQ subscales, the minimal score occurred in up to 11% at admission, while full health was observed for the EQ-5D at discharge in 13%. Sensitivity to change was generally good, whereas discrimination between COPD stages was low for the EQ-5D.

Conclusions

Acute exacerbations seriously impair health status and quality of life. The EQ-5D is generally suitable to measure HrQoL in exacerbations of severe COPD, although the high proportion of patients reporting full health at discharge poses a problem. The main issue with the SF-12 is the high proportion of missing values in a self-assessed setting. Properties of the SGRQ were satisfactory. However, since no utility values can be derived from this disease-specific instrument, it is not suitable for cost-utility analyses in health-economic evaluations.
Appendix
Available only for authorised users
Literature
1.
go back to reference Geldmacher H, Biller H, Herbst A, Urbanski K, Allison M, Buist AS, Hohlfeld JM, Welte T: [The prevalence of chronic obstructive pulmonary disease (COPD) in Germany. Results of the BOLD study]. Dtsch Med Wochenschr 2008, 133: 2609–2614. 10.1055/s-0028-1105858PubMedCrossRef Geldmacher H, Biller H, Herbst A, Urbanski K, Allison M, Buist AS, Hohlfeld JM, Welte T: [The prevalence of chronic obstructive pulmonary disease (COPD) in Germany. Results of the BOLD study]. Dtsch Med Wochenschr 2008, 133: 2609–2614. 10.1055/s-0028-1105858PubMedCrossRef
2.
go back to reference Wedzicha JA, Seemungal TAR: COPD exacerbations: defining their cause and prevention. Lancet 2007, 370: 786–796. 10.1016/S0140-6736(07)61382-8PubMedCrossRef Wedzicha JA, Seemungal TAR: COPD exacerbations: defining their cause and prevention. Lancet 2007, 370: 786–796. 10.1016/S0140-6736(07)61382-8PubMedCrossRef
3.
go back to reference Nowak D, Dietrich ES, Oberender P, Uberla K, Reitberger U, Schlegel C, Albers F, Ruckdaschel S, Welsch R: [Cost-of-illness Study for the Treatment of COPD in Germany]. Pneumologie 2004, 58: 837–844. 10.1055/s-2004-830143PubMedCrossRef Nowak D, Dietrich ES, Oberender P, Uberla K, Reitberger U, Schlegel C, Albers F, Ruckdaschel S, Welsch R: [Cost-of-illness Study for the Treatment of COPD in Germany]. Pneumologie 2004, 58: 837–844. 10.1055/s-2004-830143PubMedCrossRef
4.
go back to reference Rutten-van Molken MP, Oostenbrink JB, Tashkin DP, Burkhart D, Monz BU: Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest 2006, 130: 1117–1128. 10.1378/chest.130.4.1117PubMedCrossRef Rutten-van Molken MP, Oostenbrink JB, Tashkin DP, Burkhart D, Monz BU: Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest 2006, 130: 1117–1128. 10.1378/chest.130.4.1117PubMedCrossRef
5.
go back to reference Stahl E, Lindberg A, Jansson SA, Ronmark E, Svensson K, Andersson F, Lofdahl CG, Lundback B: Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes 2005, 3: 56. 10.1186/1477-7525-3-56PubMedCentralPubMedCrossRef Stahl E, Lindberg A, Jansson SA, Ronmark E, Svensson K, Andersson F, Lofdahl CG, Lundback B: Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes 2005, 3: 56. 10.1186/1477-7525-3-56PubMedCentralPubMedCrossRef
6.
go back to reference Garrido P, Diez J, Gutierrez J, Centeno A, Vazquez E, de Miguel A, Carballo M, Garcia R: Negative impact of chronic obstructive pulmonary disease on the health-related quality of life of patients. Results of the EPIDEPOC study. Health Qual Life Outcomes 2006, 4: 31. 10.1186/1477-7525-4-31PubMedCentralCrossRef Garrido P, Diez J, Gutierrez J, Centeno A, Vazquez E, de Miguel A, Carballo M, Garcia R: Negative impact of chronic obstructive pulmonary disease on the health-related quality of life of patients. Results of the EPIDEPOC study. Health Qual Life Outcomes 2006, 4: 31. 10.1186/1477-7525-4-31PubMedCentralCrossRef
7.
go back to reference Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C: Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003, 361: 449–456. 10.1016/S0140-6736(03)12459-2PubMedCrossRef Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C: Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003, 361: 449–456. 10.1016/S0140-6736(03)12459-2PubMedCrossRef
8.
go back to reference Szende A, Leidy N, Stahl E, Svensson K: Estimating health utilities in patients with asthma and COPD: evidence on the performance of EQ-5D and SF-6D. Qual Life Res 2009, 18: 267–272. 10.1007/s11136-008-9429-zPubMedCrossRef Szende A, Leidy N, Stahl E, Svensson K: Estimating health utilities in patients with asthma and COPD: evidence on the performance of EQ-5D and SF-6D. Qual Life Res 2009, 18: 267–272. 10.1007/s11136-008-9429-zPubMedCrossRef
9.
go back to reference Doll H, Miravitlles M: Health-related QOL in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literature. Pharmacoeconomics 2005, 23: 345–363. 10.2165/00019053-200523040-00005PubMedCrossRef Doll H, Miravitlles M: Health-related QOL in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literature. Pharmacoeconomics 2005, 23: 345–363. 10.2165/00019053-200523040-00005PubMedCrossRef
10.
go back to reference Nishimura K, Sato S, Tsukino M, Hajiro T, Ikeda A, Koyama H, Oga T: Effect of exacerbations on health status in subjects with chronic obstructive pulmonary disease. Health Qual Life Outcomes 2009, 7: 69. 10.1186/1477-7525-7-69PubMedCentralPubMedCrossRef Nishimura K, Sato S, Tsukino M, Hajiro T, Ikeda A, Koyama H, Oga T: Effect of exacerbations on health status in subjects with chronic obstructive pulmonary disease. Health Qual Life Outcomes 2009, 7: 69. 10.1186/1477-7525-7-69PubMedCentralPubMedCrossRef
11.
go back to reference Aaron SD, Vandemheen KL, Clinch JJ, Ahuja J, Brison RJ, Dickinson G, Hébert PC: Measurement of Short-term Changes in Dyspnea and Disease-Specific Quality of Life Following an Acute COPD Exacerbation. Chest 2002, 121: 688–696. 10.1378/chest.121.3.688PubMedCrossRef Aaron SD, Vandemheen KL, Clinch JJ, Ahuja J, Brison RJ, Dickinson G, Hébert PC: Measurement of Short-term Changes in Dyspnea and Disease-Specific Quality of Life Following an Acute COPD Exacerbation. Chest 2002, 121: 688–696. 10.1378/chest.121.3.688PubMedCrossRef
12.
go back to reference O'Reilly JF, Williams AE, Rice L: Health status impairment and costs associated with COPD exacerbation managed in hospital. Int J of Clin Pract 2007, 61: 1112–1120. 10.1111/j.1742-1241.2007.01424.xCrossRef O'Reilly JF, Williams AE, Rice L: Health status impairment and costs associated with COPD exacerbation managed in hospital. Int J of Clin Pract 2007, 61: 1112–1120. 10.1111/j.1742-1241.2007.01424.xCrossRef
14.
go back to reference The EuroQol Group: EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990, 16: 199–208. 10.1016/0168-8510(90)90421-9CrossRef The EuroQol Group: EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990, 16: 199–208. 10.1016/0168-8510(90)90421-9CrossRef
15.
go back to reference Greiner W, Claes C, Busschbach JJV, Graf von der Schulenburg JM: Validating the EQ-5D with Time Trade Off for the German Population. Eur J Health Econ 2005, 6: 124–130. 10.1007/s10198-004-0264-zPubMedCrossRef Greiner W, Claes C, Busschbach JJV, Graf von der Schulenburg JM: Validating the EQ-5D with Time Trade Off for the German Population. Eur J Health Econ 2005, 6: 124–130. 10.1007/s10198-004-0264-zPubMedCrossRef
16.
go back to reference Dolan P: Modeling valuations for EuroQol health states. Med Care 1997, 35: 1095–1108. 10.1097/00005650-199711000-00002PubMedCrossRef Dolan P: Modeling valuations for EuroQol health states. Med Care 1997, 35: 1095–1108. 10.1097/00005650-199711000-00002PubMedCrossRef
17.
go back to reference Brazier JE, Roberts J: The estimation of a preference-based measure of health from the SF-12. Med Care 2004, 42: 851–859. 10.1097/01.mlr.0000135827.18610.0dPubMedCrossRef Brazier JE, Roberts J: The estimation of a preference-based measure of health from the SF-12. Med Care 2004, 42: 851–859. 10.1097/01.mlr.0000135827.18610.0dPubMedCrossRef
18.
go back to reference Jones PW, Quirk FH, Baveystock CM, Littlejohns P: A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992, 145: 1321–1327.PubMedCrossRef Jones PW, Quirk FH, Baveystock CM, Littlejohns P: A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992, 145: 1321–1327.PubMedCrossRef
19.
go back to reference Tritchler D: Interpreting the standardized difference. Biometrics 1995, 51: 351–353. 10.2307/2533342PubMedCrossRef Tritchler D: Interpreting the standardized difference. Biometrics 1995, 51: 351–353. 10.2307/2533342PubMedCrossRef
20.
go back to reference Rosner B, Glynn RJ, Lee ML: The Wilcoxon signed rank test for paired comparisons of clustered data. Biometrics 2006, 62: 185–192. 10.1111/j.1541-0420.2005.00389.xPubMedCrossRef Rosner B, Glynn RJ, Lee ML: The Wilcoxon signed rank test for paired comparisons of clustered data. Biometrics 2006, 62: 185–192. 10.1111/j.1541-0420.2005.00389.xPubMedCrossRef
21.
go back to reference Rosner B, Glynn RJ, Lee ML: Incorporation of clustering effects for the Wilcoxon rank sum test: a large-sample approach. Biometrics 2003, 59: 1089–1098. 10.1111/j.0006-341X.2003.00125.xPubMedCrossRef Rosner B, Glynn RJ, Lee ML: Incorporation of clustering effects for the Wilcoxon rank sum test: a large-sample approach. Biometrics 2003, 59: 1089–1098. 10.1111/j.0006-341X.2003.00125.xPubMedCrossRef
22.
go back to reference Longworth L, Bryan S: An empirical comparison of EQ-5D and SF-6D in liver transplant patients. Health Econ 2003, 12: 1061–1067. 10.1002/hec.787PubMedCrossRef Longworth L, Bryan S: An empirical comparison of EQ-5D and SF-6D in liver transplant patients. Health Econ 2003, 12: 1061–1067. 10.1002/hec.787PubMedCrossRef
23.
go back to reference Brazier J, Roberts J, Tsuchiya A, Busschbach J: A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004, 13: 873–884. 10.1002/hec.866PubMedCrossRef Brazier J, Roberts J, Tsuchiya A, Busschbach J: A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004, 13: 873–884. 10.1002/hec.866PubMedCrossRef
24.
go back to reference Grieve R, Grishchenko M, Cairns J: SF-6D versus EQ-5D: reasons for differences in utility scores and impact on reported cost-utility. Eur J Health Econ 2009, 10: 15–23. 10.1007/s10198-008-0097-2PubMedCrossRef Grieve R, Grishchenko M, Cairns J: SF-6D versus EQ-5D: reasons for differences in utility scores and impact on reported cost-utility. Eur J Health Econ 2009, 10: 15–23. 10.1007/s10198-008-0097-2PubMedCrossRef
Metadata
Title
Health-related quality of life in patients with severe COPD hospitalized for exacerbations - comparing EQ-5D, SF-12 and SGRQ
Authors
Petra Menn
Norbert Weber
Rolf Holle
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2010
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/1477-7525-8-39

Other articles of this Issue 1/2010

Health and Quality of Life Outcomes 1/2010 Go to the issue